The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges

References

• Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):64–355. doi:10.1124/pr.115.011478
   Web of Science ®Google Scholar
• Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101(2):131–181.
   PubMed Web of Science ®Google Scholar
• Escobar JÁ, Roazzi A. Panorama contemporâneo do uso terapêutico de substâncias psicodélicas: ayahuasca e psilocibina. Neurobiologia. 2010;73(3):159–172.
   Google Scholar
• Grispoon L, Bakalar JB. Psychedelic Drugs Reconsidered. New York: Basic Books; 1979.
   Google Scholar
• Schultes RE, Hofmann A. Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers. Rochester: Healing Arts Press; 1992.
   Google Scholar
• Ott J. Pharmacotheon: drogas enteogénicas, sus fuentes vegetales y su historia (Pharmacotheon: entheogenic drugs, their plant sources and history). La Liebre de Marzo, Barcelona; 2004. Spanish.
   Google Scholar
• Dos Santos RG, Hallak JE. Therapeutic use of serotoninergic hallucinogens: a review of the evidence and of the biological and psychological mechanisms. Neurosci Biobehav Rev. 2020;108:423–434. doi:10.1016/j.neubiorev.2019.12.001
   PubMed Web of Science ®Google Scholar
• Bogenschutz MP, Ross S. Therapeutic applications of classic hallucinogens. Curr Topics Behav Neurosci. 2018;36:361–391.
   PubMedGoogle Scholar
• Liechti ME, Dolder PC, Schmid Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology (Berl). 2017;234(9–10):1499–1510. doi:10.1007/s00213-016-4453-0
   PubMed Web of Science ®Google Scholar
• Dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ, Hallak JE. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert Rev Clin Pharmacol. 2018;11:889–902. doi:10.1080/17512433.2018.1511424
   PubMed Web of Science ®Google Scholar
• Timmermann C, Roseman L, Williams L, et al. DMT models the near-death experience. Front Psychol. 2018;9. doi:10.3389/fpsyg.2018.01424
   Web of Science ®Google Scholar
• Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603–620. doi:10.1177/0269881108093587
   PubMed Web of Science ®Google Scholar
• Dos Santos RG, Osório FL, Crippa JA, Hallak JE. Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. Rev Bras Psiquiatr. 2016a;38:65–72. doi:10.1590/1516-4446-2015-1701
   PubMed Web of Science ®Google Scholar
• Barker SA. N, N-dimethyltryptamine (DMT), an endogenous hallucinogen: past, present, and future research to determine its role and function. Front Neurosci. 2018;12:536. doi:10.3389/fnins.2018.00536
   PubMed Web of Science ®Google Scholar
• Cohen S. The Beyond Within, the LSD Story. New York: Atheneum; 1967.
   Google Scholar
• Carhart-Harris RL, Nutt DJ. Serotonin and brain function: a tale of two receptors. J Psychopharmacol. 2017;31(9):1091–1120. doi:10.1177/0269881117725915
   PubMed Web of Science ®Google Scholar
• Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2020. doi:10.1001/jamapsychiatry.2020.3285
   Web of Science ®Google Scholar
• Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–1197. doi:10.1177/0269881116675513
   PubMed Web of Science ®Google Scholar
• Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–1180. doi:10.1177/0269881116675512
   PubMed Web of Science ®Google Scholar
• Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289–299. doi:10.1177/0269881114565144
   PubMed Web of Science ®Google Scholar
• Johnson MW, Garcia-Romeu A, Cosimano MP, et al. Pilot study of the 5-HT2A agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983–992. doi:10.1177/0269881114548296
   PubMed Web of Science ®Google Scholar
• Krebs TS, Johansen PØ. Psychedelics and mental health: a population study. PLoS One. 2013;8(8):e63972. doi:10.1371/journal.pone.0063972
   PubMed Web of Science ®Google Scholar
• Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202(7):513–520. doi:10.1097/NMD.0000000000000113
   PubMed Web of Science ®Google Scholar
• Dos Santos RG, Landeira-Fernandez J, Strassman RJ, et al. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J Ethnopharmacol. 2007;112(3):507–513. doi:10.1016/j.jep.2007.04.012
   PubMed Web of Science ®Google Scholar
• Sanches RF, De Lima Osório F, Dos Santos RG, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol. 2016;36(1):77–81. doi:10.1097/JCP.0000000000000436
   PubMed Web of Science ®Google Scholar
• Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655–663. doi:10.1017/S0033291718001356
   PubMed Web of Science ®Google Scholar
• Zeifman RJ, Palhano-Fontes F, Hallak J, Arcoverde E, Maia-Oliveira JP, Araujo DB. The impact of ayahuasca on suicidality: results from a randomized controlled trial. Front Pharmacol. 2019;10:1325. doi:10.3389/fphar.2019.01325
   PubMed Web of Science ®Google Scholar
• Zeifman RJ, Singhal N, Dos Santos RG, et al. Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial. Psychopharmacology (Berl). 2020;238(2):453–459. doi:10.1007/s00213-020-05692-9
   Web of Science ®Google Scholar
• Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs. 1986;18(4):305–313. doi:10.1080/02791072.1986.10472362
   PubMed Web of Science ®Google Scholar
• Danforth AL, Grob CS, Struble C, et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology (Berl). 2018;235(11):3137–3148. doi:10.1007/s00213-018-5010-9
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Mithoefer AT, Feduccia AA, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, Phase 2 clinical trial. Lancet Psychiatry. 2018;5(6):486–497. doi:10.1016/S2215-0366(18)30135-4
   PubMed Web of Science ®Google Scholar
• Reiff CM, Richman EE, Nemeroff CB, et al. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. 2020;177(5):391–410. doi:10.1176/appi.ajp.2019.19010035
   PubMed Web of Science ®Google Scholar
• de la Torre R, Farré M, Roset PN, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004;26(2):137–144. doi:10.1097/00007691-200404000-00009
   PubMed Web of Science ®Google Scholar
• Nardou R, Lewis EM, Rothhaas R, et al. Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature. 2019;569(7754):116–120. doi:10.1038/s41586-019-1075-9
   PubMed Web of Science ®Google Scholar
• Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms?. Prog Neuropsychopharmacol Biol Psychiatry. 2018;84:221–228. doi:10.1016/j.pnpbp.2018.03.003
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Leenders KL, Scharfetter C, et al. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyper frontality and psychopathology in the psilocybin model of psychosis. Neuro Psychopharmacol. 1998;16(5):357–372. doi:10.1016/S0893-133X(96)00246-1
   Web of Science ®Google Scholar
• Preller KH, Herdener M, Pokorny T, et al. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol. 2017;27(3):451–457. doi:10.1016/j.cub.2016.12.030
   PubMed Web of Science ®Google Scholar
• Rickli A, Moning OD, Hoener MC, et al. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 2016;26(8):1327–1337. doi:10.1016/j.euroneuro.2016.05.001
   PubMed Web of Science ®Google Scholar
• Marek GJ. Interactions of hallucinogens with the glutamatergic system: permissive network effects mediated through cortical layer V pyramidal neurons. Curr Top Behav Neurosci. 2018;36:107–135.
   PubMedGoogle Scholar
• Bouso JC, Fábregas JM, Antonijoan RM, et al. Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users. Psychopharmacology. 2013;230(3):415–424. doi:10.1007/s00213-013-3167-9
   PubMed Web of Science ®Google Scholar
• Ly C, Greb AC, Cameron LP, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23(11):3170–3182. doi:10.1016/j.celrep.2018.05.022
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Leech R, Hellyer PJ, et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci. 2014;8:20. doi:10.3389/fnhum.2014.00020
   PubMed Web of Science ®Google Scholar
• Palhano-Fontes F, Andrade KC, Tofoli LF, et al. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One. 2015;10(2):e0118143. doi:10.1371/journal.pone.0118143
   PubMed Web of Science ®Google Scholar
• Pasquini L, Palhano-Fontes F, Araujo DB. Subacute effects of the psychedelic ayahuasca on the salience and default mode networks. J Psychopharmacol. 2020;34(6):623–635. doi:10.1177/0269881120909409
   PubMed Web of Science ®Google Scholar
• Galvao ACM, de Almeida RN, Silva E, et al. Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls. Front Psychiatry. 2018;9:185. doi:10.3389/fpsyt.2018.00185
   PubMed Web of Science ®Google Scholar
• de Almeida RN, Galvao ACM, da Silva FS, et al. Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial. Front Psychol. 2019;10:1234. doi:10.3389/fpsyg.2019.01234
   PubMed Web of Science ®Google Scholar
• Galvao-Coelho NL, de Menezes Galvao AC, de Almeida RN, et al. Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. J Psychopharmacol. 2020;34(10):1125–1133. doi:10.1177/0269881120936486
   PubMed Web of Science ®Google Scholar
• De araujo DB, Ribeiro S, Cecchi GA, et al. Seeing with the eyes shut: neural basis of enhanced imagery following Ayahuasca ingestion. Hum Brain Mapp. 2012;33(11):2550–2560. doi:10.1002/hbm.21381
   Web of Science ®Google Scholar
• Rocha JM, Osório FL, Crippa JA, et al. Serotonergic hallucinogens and recognition of facial expressions. Therapy Adv Psychopharmacol. 2019;9:2045125319845774. doi:10.1177/2045125319845774.
   Web of Science ®Google Scholar
• Kometer M, Schmidt A, Bachmann R, et al. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic sub receptors. Biol Psychiatry. 2012;72(11):898–906. doi:10.1016/j.biopsych.2012.04.005
   PubMed Web of Science ®Google Scholar
• Gonzalez D, Cantillo J, Perez I, et al. Therapeutic potential of ayahuasca in grief: a prospective, observational study. Psychopharmacology (Berl). 2020;237(4):1171–1182. doi:10.1007/s00213-019-05446-2
   Web of Science ®Google Scholar
• Sampedro F, Revenga MF, Valle M, Roberto N, Domínguez-Clavé E, Elices M. Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities. Int J Neuropsychopharmacol. 2017;20(9):698–711. doi:10.1093/ijnp/pyx036
   PubMed Web of Science ®Google Scholar
• Soler J, Elices M, Franquesa A, et al. Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities. Psychopharmacology (Berl). 2016;233(5):823–829. doi:10.1007/s00213-015-4162-0
   PubMed Web of Science ®Google Scholar
• Soler J, Elices M, Dominguez-Clave E, et al. Four weekly Ayahuasca sessions lead to increases in “Acceptance” capacities: a comparison study with a standard 8-week mindfulness training program. Front Pharmacol. 2018;9:224. doi:10.3389/fphar.2018.00224
   PubMed Web of Science ®Google Scholar
• Franquesa A, Sainz-Cort A, Gandy S, Soler J, Alcazar-Corcoles MA, Bouso JC. Psychological variables implied in the therapeutic effect of ayahuasca: a contextual approach. Psychiatry Res. 2018;264:334–339. doi:10.1016/j.psychres.2018.04.012
   PubMed Web of Science ®Google Scholar
• Aixalà M, dos Santos RG, Hallak JEC, Bouso JC. Psychedelics and personality. ACS Chem Neurosci. 2018;9(10):2304–2306. doi:10.1021/acschemneuro.8b00237
   Web of Science ®Google Scholar
• Bouso JC, Dos Santos RG, Alcázar-Córcoles MA, et al. Serotonergic psychedelics and personality: a systematic review of contemporary research. Neurosci Biobehav Rev. 2018;87:118–132. doi:10.1016/j.neubiorev.2018.02.004
   PubMed Web of Science ®Google Scholar
• Gøtzsche PC. Deadly Psychiatry and Organised Denial. People’s Press; 2015.
   Google Scholar
• Jerome L, Feduccia AA, Wang JB, et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl). 2020;237(8):2485–2497. doi:10.1007/s00213-020-05548-2
   PubMed Web of Science ®Google Scholar
• Morales-Garcia JA, Calleja-Conde J, Lopez-Moreno JA, et al. N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo. Transl Psychiatry. 2020;10(1):1–14. doi:10.1038/s41398-020-01011-0
   Web of Science ®Google Scholar
• Oña G, Bouso JC. Psychedelic drugs as a long-needed innovation in psychiatry. Qeios. 2020. doi:10.32388/T3EM5E.2
   Google Scholar
• Johansen P-Ø, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: a population study. J Psychopharmacol. 2015;29(3):270–279. doi:10.1177/0269881114568039
   PubMed Web of Science ®Google Scholar
• Ona G, Kohek M, Massaguer T, et al. Ayahuasca and public health: health status, psychosocial well-being, lifestyle, and coping strategies in a large sample of ritual ayahuasca users. J Psychoactive Drugs. 2019;51:135–145. doi:10.1080/02791072.2019.1567961
   PubMed Web of Science ®Google Scholar
• Jiménez-Garrido DF, Gómez-Sousa M, Ona G, et al. Effects of ayahuasca on mental health and quality of life in naïve users: a longitudinal and cross-sectional study combination. Sci Rep. 2020;10:4075. doi:10.1038/s41598-020-61169-x
   Web of Science ®Google Scholar
• Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol. 2015;29(3):280–288. doi:10.1177/0269881114565653
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354. doi:10.1016/S0006-3223(99)00230-9
   PubMed Web of Science ®Google Scholar
• Jauhar S, Morrison P. Esketamine for treatment resistant depression. BMJ. 2019;366:l55–72.
   Google Scholar
• Dos Santos RG, Grasa E, Valle M, et al. Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology. 2012;219:1039–1053. doi:10.1007/s00213-011-2434-x
   PubMed Web of Science ®Google Scholar
• Fábregas JM, González D, Fondevila S, et al. Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend. 2010;111(3):257–261. doi:10.1016/j.drugalcdep.2010.03.024
   PubMed Web of Science ®Google Scholar
• Rodd R. Reassessing the cultural and psychopharmacological significance of Banisteriopsis caapi: preparation, classification and use among the Piaroa of Southern Venezuela. J Psychoactive Drugs. 2008;40(3):301–307. doi:10.1080/02791072.2008.10400645
   PubMed Web of Science ®Google Scholar
• Kjellgren A, Eriksson A, Norlander T. Experiences of encounters with ayahuasca–”the vine of the soul”. J Psychoactive Drugs. 2009;41(4):309–315. doi:10.1080/02791072.2009.10399767
   PubMed Web of Science ®Google Scholar
• Labate BC, MacRae E, editors. Ayahuasca, Ritual and Religion in Brazil. London: Equinox; 2010.
   Google Scholar
• Luna LE. Indigenous and mestizo use of Ayahuasca: an overview. In: Dos Santos RG, editor. The Ethnopharmacology of Ayahuasca. Trivandrum: Transworld Research Network; 2011.
   Google Scholar
• Labate BC, Feeney K. Ayahuasca and the process of regulation in Brazil and internationally: implications and challenges. Int J Drug Policy. 2012;23(2):154–161. doi:10.1016/j.drugpo.2011.06.006
   PubMed Web of Science ®Google Scholar
• Rucker JJ. Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential. BMJ. 2015;350:h2902. doi:10.1136/bmj.h2902
   Web of Science ®Google Scholar
• Sessa B. Turn on and tune in to evidence-based psychedelic research. Lancet Psychiatry. 2015;2(1):10–12. doi:10.1016/S2215-0366(14)00120-5
   PubMed Web of Science ®Google Scholar
• Schmid Y, Gasser P, Oehen P, Liechti ME. Acute subjective effects in LSD- and MDMA-assisted psychotherapy. J Psychopharmacol. 2020;026988112095960. doi:10.1177/0269881120959604
   Web of Science ®Google Scholar
• Bouso JC, Sánchez-Avilés C. Traditional healing practices involving psychoactive plants and the global mental health agenda: opportunities, pitfalls, and challenges in the “right to science” framework. Perspect Mental Health Human Rights. 2020;22(1):145–150.
   PubMed Web of Science ®Google Scholar
• Bonson KR. Regulation of human research with LSD in the United States (1949–1987). Psychopharmacology (Berl). 2018;235(2):591–604. doi:10.1007/s00213-017-4777-4
   Web of Science ®Google Scholar
• Richert L, Dyck E. Psychedelic crossings: American mental health and LSD in the 1970s. Med Humanit. 2020;46(3):184–191. doi:10.1136/medhum-2018-011593
   Web of Science ®Google Scholar
• Sánchez C, Bouso JC. Drug Policy Briefing: ayahuasca: from the Amazon to the Global Village. Drug Policy Briefing. 2015.
   Google Scholar
• Global psychedelic therapeutics market, 2020–2030 [homepage on the Internet]. Available from: https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html. Accessed November 20, 2020.
   Google Scholar
• Bauer B. Usona follows COMPASS in receiving breakthrough therapy designation for psilocybin to treat depression. Psychedelic Sci Rev. 2019.
   Google Scholar
• Berlowitz I, Walt H, Ghasarian C, O’shaughnessy DM, Mabit EJ, Rush FB. Who turns to Amazonian medicine for treatment of substance use disorder? Patient characteristics at the Takiwasi addiction treatment center. J Stud Alcohol Drugs. 2020;81(4):416–425. doi:10.15288/jsad.2020.81.416
   PubMed Web of Science ®Google Scholar